Ionis Pharmaceuticals

$67.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (0.16%) Today
$0.00 (0.00%) As of 4:27 PM EDT after-hours

Why Robinhood?

You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Employees
737
Headquarters
Carlsbad, California
Founded
1989
Market Cap
9.55B
Price-Earnings Ratio
24.40
Dividend Yield
0.00
Average Volume
1.00M
High Today
$69.27
Low Today
$67.44
Open Price
$67.92
Volume
1.10M
52 Week High
$86.58
52 Week Low
$43.27

Collections

IONS News

ReutersAug 14

Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT

7

IONS Earnings

-$0.27
$0.03
$0.32
$0.62
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
β€”
Actual
Expected Nov 5, Pre-Market

More IONS News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.